Skip to main content
SpringerLink
Log in

A case report of cladribine‐induced IgG4-associated liver injury 

  • Correspondence
  • Published:
Acta Neurologica Belgica Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Data Availability

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

References

  1. Biolato M, Bianco A, Lucchini M, Gasbarrini A, Mirabella M, Grieco A (2021) The disease-modifying therapies of relapsing-remitting multiple sclerosis and liver injury: a narrative review. CNS Drugs. https://doi.org/10.1007/s40263-021-00842-9

    Article  PubMed  PubMed Central  Google Scholar 

  2. Velișcu EM, Liguori V, Anatriello A, Maniscalco GT, Cantone A, Di Costanzo L, Stefanelli P, Scavone C, Capuano A (2023) Hepatobiliary adverse reactions during treatment with cladribine: analysis of data from the european spontaneous reporting system. Pharmaceuticals (Basel). https://doi.org/10.3390/ph16081071

    Article  PubMed  Google Scholar 

  3. Zanetta C, Rocca MA, Meani A, Martinelli V, Ferrè L, Moiola L, Filippi M (2023) Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study. J Neurol. https://doi.org/10.1007/s00415-023-11700-7

    Article  PubMed  PubMed Central  Google Scholar 

  4. European Medicines Agency (EMA). Direct healthcare professional communication (DHPC): Mavenclad (cladribine)—risk of serious liver injury and new recommendations about liver function monitoring. First published: 14/02/2022

  5. Meunier L, Larrey D (2023) Hepatotoxicity of drugs used in multiple sclerosis, diagnostic challenge, and the role of HLA genotype susceptibility. Int J Mol Sci. https://doi.org/10.3390/ijms24010852

    Article  PubMed  PubMed Central  Google Scholar 

  6. Rakers F, Fritsch A, Herrmann A, Tannapfel A, Schwab M (2023) Oral cladribine treatment and idiosyncratic drug-induced liver injury in multiple sclerosis. BMJ Neurol Open 5(2):e000481. https://doi.org/10.1136/bmjno-2023-000481.PMID:37705760;PMCID:PMC10496679

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors of the publication would like to thank Fondazione Roma for the invaluable support for scientific research—FR-CEMAD 21-25

Funding

Not applicable.

Author information

Authors and Affiliations

  1. Department of Medical and Surgical Sciences, CEMAD, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy

    Marco Biolato & Maurizio Pompili

  2. Department of Translational Medicine and Surgery, Catholic University of Sacred Heart, Rome, Italy

    Marco Biolato, Maria Cristina Giustiniani & Maurizio Pompili

  3. Division of Neurology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo A. Gemelli 8, 00168, Rome, Italy

    Assunta Bianco & Massimiliano Mirabella

  4. Department of Neurosciences, Multiple Sclerosis Research Center (CERSM), Catholic University of Sacred Heart, Rome, Italy

    Assunta Bianco & Massimiliano Mirabella

  5. Department of Pathology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy

    Maria Cristina Giustiniani

Authors
  1. Marco Biolato
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Assunta Bianco
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maria Cristina Giustiniani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Massimiliano Mirabella
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Maurizio Pompili
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

M.B. and A.B. wrote the main manuscript. M.C.G prepared the figure. M.M. and M.P. revised manuscript for important intellectual contributions. All authors approved the final version of the manuscript.

Corresponding author

Correspondence to Marco Biolato.

Ethics declarations

Conflict of interest

AB has served on advisory boards and/or has received travel grants and/or speaker honoraria from Merck, Biogen, Almirall, Novartis, and Sanofi-Genzyme. MM: scientific advisory board membership of Bayer Schering, Biogen, Sanofi-Genzyme, Merck, Novartis, Teva; consulting and/or speaking fees, research support or travel grants from Almirall, Bayer Schering, Biogen, CSL Behring, Sanofi-Genzyme, Merck, Novartis, Teva, Roche, Ultragenix; principal investigator in clinical trials for Biogen, Merck, Novartis, Roche, Sanofi Genzyme, Teva, Ultragenix, and CSL Behring. The rest of the authors have nothing to declare.

Ethical approval

The patient has provided informed consent for publication of the case.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Biolato, M., Bianco, A., Giustiniani, M.C. et al. A case report of cladribine‐induced IgG4-associated liver injury . Acta Neurol Belg (2024). https://doi.org/10.1007/s13760-024-02551-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s13760-024-02551-8

Keywords

Search

Navigation